ANGLE PLC, a leading liquid biopsy company, has published a peer-reviewed paper in the journal "Current Issues in Molecular Biology" highlighting the potential utility of its Parsortix® system in precision oncology. The paper showcases breakthrough data from a workflow for real-time parallel Next Generation Sequencing (NGS) DNA analysis of both circulating tumor cells (CTCs) and cell-free DNA (ctDNA) from a single tube of patient blood. The research, conducted by multiple independent cancer centers, demonstrates the value of a dual analyte approach for both CTCs and ctDNA.

The review article presents evidence of DNA variants exclusive to CTCs, compared to ctDNA, and the combined molecular analysis of CTCs and ctDNA increasing the identification of potentially actionable biomarkers. This comprehensive gene variant profile has the potential to inform prognosis, treatment selection, and monitoring of treatment resistance and disease relapse. The Parsortix system's label-free microfluidic isolation allows intact and undamaged CTCs to be harvested, providing easily accessible samples for molecular analysis with low white blood cell background.

The paper contextualizes these findings within the field of liquid biopsies, emphasizing the complementary and additive information provided by CTCs and ctDNA. Additionally, harvested CTCs can undergo RNA, protein, and morphological analysis, combining genotype with phenotype to provide a comprehensive biomarker profile. These advancements in molecular oncology, combined with broad phenotyping, are driving the implementation of precision oncology to improve patient care.

ANGLE's Chief Scientific Officer, Karen Miller, highlighted the increasing importance of CTCs in extracting genomic and phenotypic profiling information, potentially guiding patient management decisions in ways not possible using only ctDNA. The peer-reviewed journal article, "Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix System," is available through Open Access on the company's website.

ANGLE is a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for use in research, drug development, and clinical oncology. Its FDA cleared and patent-protected Parsortix® PC1 System enables complete downstream analysis of samples, including whole cell imaging, proteomic analysis, and full genomic and transcriptomic molecular analysis. The company's commercial businesses focus on diagnostic products and clinical services, with over 90 peer-reviewed publications demonstrating the performance of the Parsortix system.